Coverage
-
December 15, 2016
A federal jury took less than two hours Thursday to award Idenix Pharmaceuticals LLC a $2.54 billion royalty share of Gilead Sciences Inc.'s profits from two blockbuster hepatitis C drugs, after almost nine days of courtroom battling over claims that included willful patent infringement by Gilead.
8 other articles on this case.
View all »